Baxter

Baxter Reports First-Quarter 2024 Results

Retrieved on: 
Giovedì, Maggio 2, 2024
Medical Supplies, Medical Devices, Health, Pharmaceutical, Optical, Biotechnology, Sale, FDA, Baxter, Pharmacist, Sodium chloride, Food, Growth, LVP, SYR, Novum, Baxter International, Nursing, Patient, EPS, CDT, BPS, GAAP, Food and Drug Administration, Vasopressin

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.
  • Regardless of the selected path, Baxter currently expects the separation of its Kidney Care business to take place in the second half of 2024.
  • For full-year 2024: Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis.
  • A webcast of Baxter’s first-quarter 2024 conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on May 2, 2024.

Spectral Medical Provides Tigris Trial Update

Retrieved on: 
Mercoledì, Aprile 10, 2024
Baxter, Randomized controlled trial, Septic shock, TSX, Patient, Sepsis, Lipopolysaccharide, Pharmaceutical industry

TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Key Points: 
  • TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
  • Robust enrollment activity continues throughout 2024:
    With 49 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial
    In-person meeting well attended with multiple stakeholders present, including: principal investigators and clinical research coordinators from existing and new trial sites; CRO, Beaufort; and representatives from the Company’s strategic partner Baxter
    Currently 22 Tigris trial sites, with continued progress opening an additional two new, high quality clinical sites

IHI and The DAISY Foundation™ Honor Extraordinary Nurses in Patient Safety

Retrieved on: 
Martedì, Aprile 23, 2024
Nursing, Hospitals, Practice Management, Other Health, Managed Care, Health, General Health, Other Science, Science, DAISY, Baxter, Safety, DNP, MSN, CPPS, Pneumonia, RNS, Communication, Morale, Children's National Hospital, Patient safety, Culture, IHI, Patient, Fatigue, RN, American University of Beirut, CPAC, Workforce, Organization, American University

The Institute for Healthcare Improvement (IHI) and The DAISY Foundation today announced the recipients of the 10th annual DAISY Award® for Extraordinary Nurses in Patient Safety.

Key Points: 
  • The Institute for Healthcare Improvement (IHI) and The DAISY Foundation today announced the recipients of the 10th annual DAISY Award® for Extraordinary Nurses in Patient Safety.
  • Presented in collaboration with IHI, the DAISY Awards will be bestowed at the IHI Patient Safety Congress 2024 , which will take place May 14-16 in Orlando, Florida.
  • Each year, The DAISY Award for Extraordinary Nurses in Patient Safety celebrates nurses and clinical teams for their commitment to patient and workforce safety in the delivery of compassionate care for patients and families.
  • “All of us at IHI and The DAISY Foundation commend the awardees for being caring and compassionate nurses, and stewards of patient and workforce safety.”
    The DAISY Award for Extraordinary Nurses in Patient Safety is supported by a generous grant from Baxter , a global provider of clinical technology and patient safety solutions.

Sofinnova Partners Appoints Two New Partners Strengthening Team of Next Generation Investors

Retrieved on: 
Lunedì, Aprile 22, 2024
Professional Services, Health, Other Professional Services, Environment, Sustainability, Other Health, Finance, Baxter, Sofinnova, Biotechnology, Chemical industry, Doctor of Philosophy, Growth, Imperial College London, Myocardial infarction, Heart failure, Renewable energy

These promotions underscore Sofinnova's dedication to developing talent from within its own ranks and commitment to driving impactful change in the sector.

Key Points: 
  • These promotions underscore Sofinnova's dedication to developing talent from within its own ranks and commitment to driving impactful change in the sector.
  • Gkelou joined Sofinnova as an Analyst in the Capital Strategy in 2017 after working as an immunology scientist at Danone Nutricia.
  • As a Partner in the Capital Strategy, Gkelou will play a key role in investing in the next generation of early-stage biotech companies.
  • "I am honored to have been part of the Industrial Biotechnology team since its early days," Baxter said.

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

Retrieved on: 
Lunedì, Aprile 15, 2024
Medical Devices, Medical Supplies, Hospitals, Practice Management, Other Health, Biotechnology, Managed Care, General Health, Health, Oncology, Baxter International, FP, Baxter, CFO, Cancer, Patient, Science, Growth, 3M, Exact sciences, Management

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.

Key Points: 
  • Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.
  • Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience.
  • At Baxter, Mr. Bloomer led corporate financial planning, reporting, and analytics (FP&A) as vice president.
  • “Aaron comes to us with significant global experience setting corporate strategy and driving growth and operational discipline from his leadership roles at incredible companies,” said Kevin Conroy, chairman and chief executive officer of Exact Sciences.

Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Retrieved on: 
Giovedì, Aprile 11, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, FDA, Baxter, USP, Sodium chloride, Injection, Blood pressure, Baxter International, Anesthesia, Patient, Regadenoson, Antimalarial medication, Infection, Hypotension, Catecholamine, Vasopressin, Vancomycin, Pharmaceutical industry

“We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”

Key Points: 
  • “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
    Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
  • For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
  • Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
  • Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.

Ascend Hires Scott Law as COO and Continues Strengthening Foundation

Retrieved on: 
Mercoledì, Aprile 24, 2024
Baxter, Emergent, AAV, San Francisco Bay Area, QC, Acquisition, GMP

LONDON, April 24, 2024 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has announced the addition of industry veteran Scott Law as Chief Operations Officer (COO).

Key Points: 
  • LONDON, April 24, 2024 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has announced the addition of industry veteran Scott Law as Chief Operations Officer (COO).
  • Scott brings more than 30 years of global pharmaceutical experience, including senior manufacturing roles at companies such as Telix Pharmaceuticals, Baxter, Emergent BioSolutions, Ferndale Laboratories, and Pfizer.
  • The addition of Scott further elevates our depth of talent in this market, which is a key differentiator and mainstay of the foundation at Ascend."
  • We also must have the right level of expertise and execution to continue growing our position as the leading AAV CDMO," new COO, Scott Law offered.

AI for the Service Supply Chain

Retrieved on: 
Mercoledì, Aprile 10, 2024
Baxter, SLA, AI, LTB, Nobel Prize, New product development, The Last Time, NPI

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Baxter Planning, the leading provider of Service Supply Chain technology, today announced the general availability of our latest Artificial Intelligence-driven solution, BaxterPredict Prophet.ai.

Key Points: 
  • AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Baxter Planning, the leading provider of Service Supply Chain technology, today announced the general availability of our latest Artificial Intelligence-driven solution, BaxterPredict Prophet.ai.
  • Powered by AI and Baxter Planning's unique Service Supply Chain domain expertise, BaxterPredict Prophet.ai allows its users to:
    "This technology could be a real game changer for us.
  • The Baxter Planning team has been dedicated to partnering with its Service Supply Chain customers and has found real value and opportunity with this application of AI into its products.
  • The company plans to invest further in AI for a variety of use cases to truly optimize Service Supply Chains.

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Retrieved on: 
Giovedì, Marzo 28, 2024
Emory Healthcare, Sepsis, Conference, SAMI, Motivation, Clinical professor, Partnership, Patient, EAA, Mayo Clinic, Mortality, Septic shock, EDEN, University, Spectral, Intensive care unit, Critical care, PMX, AME Publishing Company, TSX, Clinical trial, Nephrology, ICU, FDA, UCLA, Baxter, Marketing, Economics, Hemoperfusion, Pharmaceutical industry

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
  • Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We have witnessed robust enrollment activity to start 2024.
  • addition of two new trial sites in the fourth quarter – the Mayo Clinic and Emory Healthcare.
  • The Company concluded the 2023 year with cash of $2,952,000 compared to $8,414,000 cash on hand as of December 31, 2022.

Pharmacy Automation: Technologies and Global Markets Report 2024-2028 Featuring Major Players - BD, Baxter, Omnicell, and KUKA - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Aprile 3, 2024
Health, Pharmaceutical, RFID, Automation, Omnicell, Drug discovery, Internet of things, KUKA, ESG, Pharmacy, Internet, Artificial intelligence, Pharmacist, Workflow, Cloud computing, Growth, USD, Baxter, Approximation error

The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacy Automation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pharmacy Automation Market was valued at USD 7.8 Billion in 2023, and is expected to reach USD 12.7 Billion by 2028, rising at a CAGR of 10.20%.
  • This report is designed to be a helpful business tool that will provide a thorough evaluation of the global pharmacy automation market.
  • Definitive and detailed estimates and forecasts of the global market are provided, followed by a detailed analysis of segments and regions.